Communicable Disease Epidemiology and Immunization Section

401 5th Avenue, Suite 1250 Seattle, WA 98104

206-296-4774 Fax 206-296-4803

TTY Relay: 711

www.kingcounty.gov/health



Health Advisory - Candida auris identified in Oregon, 4 January, 2021

Action Requested

- Be aware that <u>Candida auris</u> was recently detected in a patient in <u>Oregon</u>, with subsequent healthcare-associated transmission to other patients.
- Be aware of growing concerns for multidrug-resistant *C. auris* infections in the U.S.
- Consultation with an ID specialist and Public Health Seattle and King County is highly recommended when *C. auris* colonization or infection is suspected to ensure appropriate testing and treatment.
- Consider C. auris screening in patients at high risk for C. auris, including those who had:
 - Close contact in a healthcare setting to someone diagnosed with *C. auris* infection or colonization
 - An overnight stay in a healthcare facility outside the U.S. or in a <u>region within the</u>
 U.S. with documented *C. auris* cases in the previous year.
- Inquire about the above high risk exposures in all newly admitted patients.
- Coordinate C. auris screening and testing with Public Health at (206) 296-4774.
- Be aware that *C. auris* can be misidentified through laboratory testing as a number of different organisms and <u>specific technology</u> is <u>needed</u>.
- Remain vigilant for any increase in infections due to unidentified *Candida* species in a patient care unit, including from urine specimens, and consider *C. auris* since it can be transmitted in healthcare settings.
- Patients in hospitals with suspected or confirmed *C. auris* should be managed using contact precautions, and placed in a single room whenever possible.
- Reinforce and audit core <u>infection prevention practices in healthcare facilities</u>.
- Communicate information about colonization or infection with *C. auris* during care transitions within and transfers between healthcare settings. CDC Interfacility transfer form
- Please immediately report any suspected or confirmed *C. auris* cases or outbreaks to Public Health at (206) 296-4774.

Background

Since its discovery in 2009, <u>C. auris</u> has emerged globally as a life-threatening, highly transmissible, often multidrug resistant yeast. In the past year CDC has published several reports of ongoing transmission of highly resistant strains of *C. auris* in United States healthcare facilities, particularly in units caring for patients recovering from COVID-19 ^{1,2,3} Patients with long term acute care and indwelling devices are at highest risk for acquisition. International healthcare is often the initial source of introduction of *C. auris* to a region. Subsequent healthcare transmission may occur due to shedding in the healthcare environment, resistance of *C. auris* to standard healthcare disinfectants, and lapses in infection control practices.

C. auris has not yet been detected in Washington but represents a serious threat. For details about where cases have been identified within the U.S., see the map here. WA DOH performs special surveillance for *C. auris* by screening isolates submitted from high risk patients and sentinel lab submissions of non-albicans Candida species to the WA Public Health Laboratory for identification.

C. auris will become a notifiable condition in WA as of January 1, 2023. In the meantime, we consider C. auris to be reportable immediately to Public Health as a 'rare condition of public health significance.' All suspected HAI outbreaks (which includes a single case of C. auris in a healthcare facility) are also required to be reported immediately to Public Health.

References

- Prestel C, Anderson E, Forsberg K, et al. Candida auris Outbreak in a COVID-19 Specialty Care Unit — Florida, July–August 2020. MMWR Morb Mortal Wkly Rep 2021;70:56–57. DOI: http://dx.doi.org/10.15585/mmwr.mm7002e3
- Lyman M, Forsberg K, Reuben J, et al. Notes from the Field: Transmission of Pan-Resistant and <u>Echinocandin-Resistant Candida auris in Health Care Facilities — Texas and the District of</u> <u>Columbia, January—April 2021. MMWR Morb Mortal Wkly Rep 2021;70:1022—1023. DOI:</u> <u>http://dx.doi.org/10.15585/mmwr.mm7029a2</u>
- Adams E, Quinn M, Tsay S, et al. Candida auris in Healthcare Facilities, New York, USA, 2013-2017. Emerg Infect Dis. 2018;24(10):1816-1824. doi: http://dx.doi.org/10.3201/eid2410.180649

Resources

- Washington State Department of Health Candida auris resources:
 https://www.doh.wa.gov/ForPublicHealthandHealthcareProviders/NotifiableConditions/Candidauris
- Candida auris testing information: https://www.doh.wa.gov/ForPublicHealthandHealthcareProviders/PublicHealthLaboratories/
 ARLNLabTestMenu#heading21551
- Environmental Protection Agency List P: Antimicrobial Products Registered with EPA for Claims Against Candida auris: https://www.epa.gov/pesticide-registration/list-p-antimicrobial-products-registered-epa-claims-against-candida-auris